Palisade Bio, Inc.
PALI
Positions held
Your positionsPALI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $252.69M | Enterprise value | $127.52M | Trailing P/E | 2.42 | Forward P/E | -5.11 |
| PEG | — | Price / book | 2.07 | Beta | 1.62 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -23.4% |
| Profit margin | 0.0% | ROE | -51.4% | ROA | -33.0% | Debt / equity | — |
| Current ratio | 24.26 | Free cash flow | -$8.65M | Analyst recommendation | strong_buy | Mean target | $10.22 |
| 52w high | $2.86 | 52w low | $1.32 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -2339.6% | — | — | — | — | — |
| Net income | -$10.6M | -$9.6M | -$8.9M | -$2.9M | -$2.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$11.7M | -$10.7M | -$10.0M | -$2.9M | -$2.8M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.3M | $0.0M | — |
| Op margin | — | — | -5138.0% | — | — |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$18.1M | -$14.9M | -$12.8M | -$15.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-27 · Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
2026-09-23 · Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada
2026-09-23 · Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
2026-09-22 · Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease
2026-09-22 · Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
2026-09-21 · Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-03 · Palisade Bio to Participate in Upcoming Investor Conferences
2026-07-27 · Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Price (daily)
Full chart · RSI · MACD · patterns